Back to search results

CART-EGFR-IL13Ra2 for Recurrent Glioblastoma

This study is testing different ways to give a treatment called CART-EGFR-IL13Ra2 T cells to people with glioblastoma (a type of brain cancer) that has come back after previous radiation therapy. CART-EGFR-IL13Ra2 T cells are your own immune cells that have been specially trained to find and fight cancer cells that have certain markers (EGFR and IL13Ra2). Researchers want to see how safe this treatment is, if it's possible to give it, and if it shows any signs of helping. They will also look at how the treatment moves through your body. You may be able to join if you are 18 or older, have recurrent glioblastoma (IDH-wildtype), and have specific markers (EGFR) on your tumor. The study will track side effects for up to 15 years.

Study design
This is an open-label, phase 1b study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 12 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be monitored for treatment-related side effects for up to 15 years after receiving CART-EGFR-IL13Ra2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07209241

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
University of Pennsylvania
~12 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:CART-EGFR-IL13Ra2 T cells

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Measured over Up to 15 years following CART-EGFR-IL13Ra2 administration
+1 more outcome measured

Conditions

Recurrent Glioblastoma

Explore related trials

GlioblastomaSoluble Epidermal Growth Factor Receptor

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Stephen Bagley, MD, MSCE · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0Up to 15 years following CART-EGFR-IL13Ra2 administration

    Type, frequency, severity, and attribution of adverse events

  • Occurrence of treatment-limiting toxicities (Arms A and B only)Up to 28 days following CART-EGFR-IL13Ra2 administration

    Type, frequency, severity, and attribution of treatment limiting adverse events as defined in protocol section 8.1.7